Diagnostic Accuracy of Amino Acid and FDG-PET in Differentiating Brain Metastasis Recurrence from Radionecrosis after Radiotherapy: A Systematic Review and Meta-Analysis
Open Access
- 14 December 2017
- journal article
- review article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 39 (2) , 280-288
Abstract
BACKGROUND: Current studies that analyze the usefulness of amino acid and FDG-PET in distinguishing brain metastasis recurrence and radionecrosis after radiation therapy are limited by small cohort size. PURPOSE: Our aim was to assess the diagnostic accuracy of amino acid and FDG-PET in differentiating brain metastasis recurrence from radionecrosis after radiation therapy. DATA SOURCES: Studies were retrieved from PubMed, Embase, and the Cochrane Library. STUDY SELECTION: Fifteen studies were included from the literature. Each study used PET to differentiate radiation necrosis from tumor recurrence in contrast-enhancing lesions on follow-up brain MR imaging after treating brain metastasis with radiation therapy. DATA ANALYSIS: Data were analyzed with a bivariate random-effects model. Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were pooled, and a summary receiver operating characteristic curve was fit to the data. DATA SYNTHESIS: The overall pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of PET were 0.85, 0.88, 7.0, 0.17, and 40, respectively. The area under the receiver operating characteristic curve was 0.93. On subgroup analysis of different tracers, amino acid and FDG-PET had similar diagnostic accuracy. Meta-regression analysis demonstrated that the method of quantification based on patient, lesion, or PET scan (based on lesion versus not, P = .07) contributed to the heterogeneity. LIMITATIONS: Our study was limited by small sample size, and 60% of the included studies were of retrospective design. CONCLUSIONS: Amino acid and FDG-PET had good diagnostic accuracy in differentiating brain metastasis recurrence from radionecrosis after radiation therapy.Keywords
This publication has 59 references indexed in Scilit:
- Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategiesNeuro-Oncology, 2013
- Comparison of 18F-Fluorodeoxyglucose and 18F-Fluorothymidine PET in Differentiating Radiation Necrosis From Recurrent GliomaClinical Nuclear Medicine, 2012
- Perfusion Computed Tomography (PCT) adopting different perfusion metrics: Recurrence of brain metastasis or radiation necrosis?European Journal of Radiology, 2012
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain MetastasesJournal of Clinical Oncology, 2012
- Radiation-induced brain injury: A reviewFrontiers in Oncology, 2012
- Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosisRadiation Oncology, 2011
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 StudyJournal of Clinical Oncology, 2011
- NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of 3′-Deoxy-3′-[18F]fluorothymidine (FLT) as a Marker of Proliferation in Patients with Recurrent Gliomas: Preliminary Efficacy StudiesMolecular Imaging and Biology, 2009
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003